Reveal undesired sub-visible particles in your sample

Control of sub-visible particles in samples of recombinant proteins and mAbs

Regulatory expectations for the control of particles have increased significantly over the last decade. Orthogonal methods are required to monitor aggregates and particulate matter in the range of 0.1-10um. Factors that can give rise to particles at different process stages are numerous. Below are some examples:

Extrinsic particles arising from the manufacturing process

  • Shear forces from pumps
  • Rubber fragments, e.g. from tubings
  • Leachables from disposable technology
  • Buffer and excipients
  • Silicon oil from syringes

Intrinsic particles due to non-optimized conditions

  • Protein  aggregates

Choose your analysis

Particle size distribution of recombinant proteins
Arrow 33.4 Created with Sketch.

MiniTEM is employed for size distribution analysis of recombinant proteins to detect deviations in size

The size distribution graph shows the number of particles of expected size as well as smaller size debris and aggregates – the data is easily correlated to the content of the acquired images.

Aggregate & particle detection
Arrow 33.4 Created with Sketch.

TEM imaging of different samples of monoclonal antibodies (mAbs)

Single mAbs in a monolayer can be observed as well as stress induced aggregates.

Virus detection in tissue sample
Arrow 33.4 Created with Sketch.

Retrovirus detection in cell sections with MiniTEM

MiniTEM can be set to automatically search for retroviruses in cell section by using machine learning technology and template matching

Sample description (optional)

Analysis objective (optional)


Study Proposal Form

Please fill out the following information with as much detail as you can, in order for us to provide you with an accurate quote as soon as possible.

* - Compulsory fields
What is the nature of the product
If relevant, where will the product be marketed
Should the study be performed in compliance with GLP
Should the study be performed in duplicate
Will a representative from your company be present during the testing
Process steps to be tested Model viruses Processing time Number of points for sampling If representative(s) will be present, please specify for which step(s)
Vironova Biosafety
Thank you for your interest.